Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
23 Dec 2022Serine protease inhibition shows promise in COVID-19
The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.
Serine protease inhibition shows promise in COVID-19
23 Dec 2022FMT offers no weight loss benefits in individuals with obesity
For individuals with obesity who are scheduled to undergo bariatric surgery, faecal microbiota transplantation (FMT) from a lean donor does not appear to help reduce weight before or after the procedure, according to a study.
FMT offers no weight loss benefits in individuals with obesity
22 Dec 2022Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
22 Dec 2022No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
22 Dec 2022Local data support continuation of RASIs in patients with T2D and advanced CKD
Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).